New drug tested for Tough-to-Treat thyroid cancer
NCT ID NCT05660954
Summary
This study is testing the drug cabozantinib for people with advanced thyroid cancer that has stopped responding to radioactive iodine and other targeted drugs. The main goal is to see if specific markers in the blood can predict how well the treatment works. Participants will take the drug daily until their cancer worsens or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Asistencial Universitario de Salamanca
Salamanca, 37007, Spain
-
Complexo Hospitalario Universitario A Coruña
A Coruña, 15006, Spain
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital General Universitario Morales Meseguer
Murcia, 30008, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, 33011, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.